Latest mRNA Vaccine for RSV Wins Expedited Review

Analysis by Dr. Joseph Mercola  Fact Checked February 09, 2023

STORY AT-A-GLANCE

Moderna just moved one step closer to bringing mRNA-1345, an RSV shot, to market
The U.S. Food and Drug Administration granted the experimental shot fast-track
designation in August 2021

Now, Moderna’s mRNA RSV shot has been given Breakthrough Therapy Designation,
which allows for faster development and an expedited review period

RSV is usually not serious; most people experience only mild, cold-like symptoms and
recover on their own in a week or two

 Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023
Along with Moderna’s mRNA RSV shot, Pfizer and GSK have also developed RSV
vaccines that are awaiting regulatory approval

You may also like these